Literature DB >> 6348779

Monoclonal IgM antibody exhibiting high-affinity binding and cryoglobulin properties.

D W Ballard, D M Kranz, E W Voss.   

Abstract

A monoclonal IgM antibody (18-2-3) derived from cell fusion of (NZB X NZW) F1 splenocytes following secondary immunization with fluorescein-conjugated keyhole limpet hemocyanin was shown to exhibit high intrinsic binding affinity and cryoinsolubility. Affinity-purified preparations were determined to be IgM by immunochemical, electrophoretic, and chromatographic analyses. An intrinsic association constant (Ka) of 2.9 X 10(10) M-1 (at 2 degrees C) was measured by first-order dissociation-rate analysis. Antibody solubility at low concentration (approximately equal to 50 micrograms/ml) was shown, by absorption spectroscopy, to be temperature dependent between 4 degrees C and 32 degrees C. Insolubility at low temperature (4 degrees C) was reversible in the presence of homologous fluorescyl hapten, indicative of active site involvement in the mechanism of cryoglobulin-18-2-3 complex formation. Characteristics of clone 18-2-3 are discussed in terms of (i) its potential use as a model for examining the mechanism of cryoprecipitation and (ii) the proposed relationship between affinity maturation and the IgM to IgG class switch.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6348779      PMCID: PMC384190          DOI: 10.1073/pnas.80.16.5071

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Fluorescein: a complete antigenic group.

Authors:  E W Voss; W Eschenfeldt; R T Root
Journal:  Immunochemistry       Date:  1976-05

Review 2.  Cell selection by antigen in the immune response.

Authors:  G W Siskind; B Benacerraf
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

Review 3.  The immunology and pathology of NZB mice.

Authors:  J B Howie; B J Helyer
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

4.  Anti-fluorescein antibody of high affinity and restricted heterogeneity as characterized by fluorescence polarization and quenching equilibrium techniques.

Authors:  A J Portmann; S A Levison; W B Dandliker
Journal:  Biochem Biophys Res Commun       Date:  1971-04-02       Impact factor: 3.575

5.  Cryoglobulins in New Zealand Black mice.

Authors:  W Hijmans; H Radema; L van Es; T E Feltkamp; J J van Loghem; O L Schaap
Journal:  Clin Exp Immunol       Date:  1969-02       Impact factor: 4.330

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Fluorescein. Hapten and antibody active-site probe.

Authors:  D E Lopatin; E W Voss
Journal:  Biochemistry       Date:  1971-01-19       Impact factor: 3.162

8.  Antibodies to major histocompatibility antigens produced by hybrid cell lines.

Authors:  G Galfre; S C Howe; C Milstein; G W Butcher; J C Howard
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

9.  Studies on the cryoprecipitation of a human IGG3 cryoglobulin: the effects of temperature-induced comformational changes on the primary interaction.

Authors:  P H Saulk; W Clem
Journal:  Immunochemistry       Date:  1975-01

10.  Natural thymocytotoxic autoantibody and reactive antigen in New Zealand black and other mice.

Authors:  T Shirai; R C Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  1971-07       Impact factor: 11.205

View more
  4 in total

1.  Manipulation of Proteins on Mica by Atomic Force Microscopy.

Authors:  A S Lea; A Pungor; V Hlady; J D Andrade; J N Herron; E W Voss
Journal:  Langmuir       Date:  1992       Impact factor: 3.882

2.  Lupus-derived autoantibodies with dual autoactivity: anti-DNA and anti-Fc. II. Fine specificity of anti-self autoreactivity.

Authors:  C A Rumbley; E W Voss
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

3.  A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: effectiveness after peripheral and central administration.

Authors:  Jean-Christophe Peter; Anne-Catherine Lecourt; Marjorie Weckering; Géraldine Zipfel; Michael L Niehoff; William A Banks; Karl G Hofbauer
Journal:  J Pharmacol Exp Ther       Date:  2010-01-29       Impact factor: 4.030

4.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.